We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OND Managed a Slew of EUAs, a Reorg, PDUFA Goals and Regular Business During Pandemic, Says Annual Report
OND Managed a Slew of EUAs, a Reorg, PDUFA Goals and Regular Business During Pandemic, Says Annual Report
Despite the unprecedented disruption and shift in priorities that COVID-19 brought to FDA’s Office of New Drugs (OND) in 2020, the office approved 53 novel drugs, published 31 new guidances and wrapped up the reorganization it had been working on since 2019, said Peter Stein, OND’s director, in the office’s annual report.